Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiazhen Cui

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
International Journal of Hematology|September 10, 2025
Sequential intrathoracic injection and intravenous infusion of BCMA CAR-T cells in a patient with relapsed/refractory primary plasma cell leukemiaWei Han, Shuyang Wang, Mingming Zhang, et al.
Eclinicalmedicine|May 30, 2023
Safety and efficacy of CRISPR-based non-viral <i>PD1</i> locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I studyYongxian Hu, Cheng Zu, Mingming Zhang, et al.
Biochemical and Biophysical Research Communications|December 19, 2020
A novel human anti-TIGIT monoclonal antibody with excellent function in eliciting NK cell-mediated antitumor immunityDong Han, Yinfeng Xu, Xinping Zhao, et al.
Chinese Medical Journal|November 6, 2024
Predictive value of pre-treatment circulating tumor DNA genomic landscape in patients with relapsed/refractory multiple myeloma undergoing anti-BCMA CAR-T therapy: Insights from tumor cells and T cellsRongrong Chen, Chunxiang Jin, Kai Liu, et al.
Cancer Immunology Research|July 22, 2021
CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy StudyGuoqing Wei, Yanlei Zhang, Houli Zhao, et al.
Bone Marrow Transplantation|March 31, 2023
HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapyShan Fu, Qiqi Zhang, Ruirui Jing, et al.
Frontiers in Immunology|May 22, 2023
Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myelomaQiqi Zhang, Cheng Zu, Ruirui Jing, et al.
Regulatory Toxicology and Pharmacology : RTP|April 26, 2020
Preclinical safety evaluation of body protective compound-157, a potential drug for treating various woundsChuanyang Xu, Lijuan Sun, FengLing Ren, et al.
International Immunopharmacology|October 24, 2022
Evaluation of Zika virus DNA vaccines based on NS1 and domain III of EGuoqing Xiong, Yi Li, Fei Chen, et al.
Cell Transplantation|January 6, 2024
Relapsed/Refractory Peripheral T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis With UNC13D and CD27 Germline MutationsTingting Yang, Rongrong Chen, Mingming Zhang, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
International Journal of Hematology|September 10, 2025
Sequential intrathoracic injection and intravenous infusion of BCMA CAR-T cells in a patient with relapsed/refractory primary plasma cell leukemiaWei Han, Shuyang Wang, Mingming Zhang, et al.
Eclinicalmedicine|May 30, 2023
Safety and efficacy of CRISPR-based non-viral <i>PD1</i> locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I studyYongxian Hu, Cheng Zu, Mingming Zhang, et al.
Biochemical and Biophysical Research Communications|December 19, 2020
A novel human anti-TIGIT monoclonal antibody with excellent function in eliciting NK cell-mediated antitumor immunityDong Han, Yinfeng Xu, Xinping Zhao, et al.
Chinese Medical Journal|November 6, 2024
Predictive value of pre-treatment circulating tumor DNA genomic landscape in patients with relapsed/refractory multiple myeloma undergoing anti-BCMA CAR-T therapy: Insights from tumor cells and T cellsRongrong Chen, Chunxiang Jin, Kai Liu, et al.
Cancer Immunology Research|July 22, 2021
CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy StudyGuoqing Wei, Yanlei Zhang, Houli Zhao, et al.
Bone Marrow Transplantation|March 31, 2023
HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapyShan Fu, Qiqi Zhang, Ruirui Jing, et al.
Frontiers in Immunology|May 22, 2023
Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myelomaQiqi Zhang, Cheng Zu, Ruirui Jing, et al.
Regulatory Toxicology and Pharmacology : RTP|April 26, 2020
Preclinical safety evaluation of body protective compound-157, a potential drug for treating various woundsChuanyang Xu, Lijuan Sun, FengLing Ren, et al.
International Immunopharmacology|October 24, 2022
Evaluation of Zika virus DNA vaccines based on NS1 and domain III of EGuoqing Xiong, Yi Li, Fei Chen, et al.
Cell Transplantation|January 6, 2024
Relapsed/Refractory Peripheral T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis With UNC13D and CD27 Germline MutationsTingting Yang, Rongrong Chen, Mingming Zhang, et al.
Pageof 6